Sanara MedTech Inc.

Sanara MedTech Inc. has terminated its Transaction Advisory Services Agreement with The Catalyst Group, Inc., effective June 2, 2026. This decision aligns with Sanara's new strategy to concentrate on soft tissue repair and bone fusion products for the surgical market. The company incurred no fees or penalties for the termination, though certain covenants like indemnification and confidentiality will remain active. Notably, Sanara's Chairman, Ronald T. Nixon, is the founder of Catalyst, which, along with its affiliates, holds more than 5% of Sanara's common stock.

Sanara MedTech Inc. reported a significant financial turnaround for the first quarter ended March 31, 2026, with net revenue increasing by 18.6% to $27.8 million and the company swinging to a net profit of $0.46 million, or $0.05 per basic share, compared to a net loss in the prior year. This improvement follows the discontinuation of the Tissue Health Plus (THP) segment in Q3 2025, which was substantially complete by year-end 2025. The company also reduced earnout liabilities to zero due to non-renewal of the Petito Services Agreement and the discontinuation of THP.

Sanara MedTech Inc. reported strong first-quarter 2026 financial results, with net revenue increasing 19% to $27.8 million and achieving GAAP net profitability of $0.04 per diluted share from continuing operations, compared to a net loss in the prior year. The company's strategic realignment to focus solely on the surgical market, coupled with sales team expansion, drove these results. Sanara MedTech reaffirmed its full-year 2026 net revenue guidance of $116 million to $121 million.

Sanara MedTech Inc. reported strong financial results for the first quarter ended March 31, 2026, with net revenue increasing 19% to $27.8 million. The company achieved GAAP net profitability from continuing operations of $0.4 million, or $0.04 per diluted share, a significant improvement from a net loss in the prior year. This performance reflects the company's sharpened focus on the surgical market and enhanced financial model. Sanara MedTech reaffirmed its full-year 2026 net revenue guidance of $116 million to $121 million, representing 13% to 17% growth.